Flow Cytometry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.
Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15 days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. This study suggests that fingolimod-immunosuppressed patients, despite the low circulating lymphocytes, may rapidly expand antibody-secreting cells and mount an effective immune response that favors COVID-19 recovery after drug discontinuation.
一名多发性硬化症患者在接受芬戈莫德治疗期间感染了 SARS-CoV-2，出现中等临床特征，15 天后康复。研究人员检测到高水平的趋化因子 CCL5 和 CCL10 以及分泌抗体的 B 细胞，而其他 B 细胞和 T 细胞亚群的水平与适当的对照相当。然而，体外刺激时，CD4+和 CD8+细胞呈寡克隆扩增且易发生凋亡。这项研究表明，尽管芬戈莫德抑制免疫的患者循环淋巴细胞数量较低，但他们可能会迅速扩增分泌抗体的细胞，并产生有效的免疫反应，有利于停药后 COVID-19 的康复。
